Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response remain unclear. Our investigation into the effects of anti-CTLA-4 and anti-PD-1 on memory T cell formation in mice reveals that memory T cells generated by anti-CTLA-4 exhibit greater expansion, cytokine production, and antitumor activity than those from anti-PD-1. Notably, anti-CTLA-4 preserves more T cell factor-1 (TCF-1)+ T cells during priming, while anti-PD-1 leads to more thymocyte selection-associated high mobility group box (TOX)+ T cells. Experiments using conditional <i>Tcf7</i>- or <i>Tox</i>-knockout mice highlight that TCF-1 is essential for the memory response generated by anti-CTLA-4, whereas TOX deletion alone in T cells has no effect on the response to anti-PD-1. Deepening our understanding of how checkpoint inhibition affects memory response is crucial for advancing our understanding of the enduring impacts of these immunotherapies on the immune system.
Authors
- Didem Ağaç Çobanoğlu (ORCID: https://orcid.org/0000-0002-3493-7024)
- James P. Allison (ORCID: https://orcid.org/0000-0001-8980-5697)
- E. John Wherry (ORCID: https://orcid.org/0000-0003-0477-1956)
- Huey Liu (ORCID: https://orcid.org/0000-0002-0752-8348)
- Nana-Ama A.S. Anang (ORCID: https://orcid.org/0000-0002-8495-2978)
- Stephen Mok
- James J. Mancuso (ORCID: https://orcid.org/0000-0001-5776-8617)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Translational Therapeutics (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1073/pnas.2418985122
- Citations
- 19
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 19.86
Funders
- Cancer Research Institute
- Cancer Prevention and Research Institute of Texas
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health
- University of Texas MD Anderson Cancer Center